TY - T1的介入时机的重要性在博来霉素模型的肺纤维化JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01105 -2019欧元六世- 55 - 6 SP - 1901105 AU -科尔布,菲利普盟——Upagupta Chandak盟——Vierhout梅根盟——Ayaub Ehab AU - Bellaye,皮埃尔西蒙盟——GauldieJack AU - Shimbori, Chiko AU - Inman, Mark AU - Ask, Kjetil AU - Kolb, Martin R.J. Y1 - 2020/06/01 UR - //www.qdcxjkg.com/content/55/6/1901105.abstract N2 -特发性肺纤维化(IPF)是一种病因不明的复杂疾病，使药物开发具有挑战性。博莱霉素单次直接给药小鼠肺是研究肺纤维化形成和评价抗纤维化治疗策略效果的广泛应用的实验模型。该模型的工作原理是诱导早期炎症期，在5-7天后转变为纤维化。这种初始炎症使得治疗时机至关重要。为了准确评估抗纤维化疗效，干预应在不影响早期炎症的情况下抑制纤维化。从PubMed检索2008年至2019年发表的使用博莱霉素模型研究肺纤维化的研究，并分析研究特征。以干预为基础的研究被分为预防性研究(在博来霉素使用后7天开始)和治疗性研究(在博来霉素使用后7天开始)。此外，研究还与当前的主要临床试验相互参照，以评估临床前理论基础的可用性。共评估了976份出版物。726种可能的治疗方法，其中443种(61.0%)为单纯预防性治疗，166种(22.9%)为单纯治疗，105种(14.5%)为两者兼用。 Of the 443 preventative studies, only 70 (15.8%) characterised inflammation during the model's early inflammatory phase. In the reported 145 IPF clinical trials investigating 93 compounds/combinations, only 25 (26.9%) interventions had any preclinical data on bleomycin available on PubMed.Since 2008, we observed a shift (from <5% to 37.4%) in the number of studies evaluating drugs in the therapeutic setting in the bleomycin model. While this shift is encouraging, further characterisation of early inflammation and appropriate preclinical therapeutic testing are still needed. This will facilitate fruitful drug development in IPF, and more therapeutic strategies for patients with this devastating disease.Preclinical models are important to decipher mechanisms of disease, identify novel treatment targets and develop new drugs. The bleomycin model is the standard model for pulmonary fibrosis, but it is often used incorrectly, as shown by this meta-analysis. http://bit.ly/39qboxP ER -